NCT06453928

Starting Technology in At Risk Type 1 Diabetes Study

Starting Technology in At Risk Type 1 Diabetes (STAR-T1D) Study

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: University of California, Los Angeles · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Diabetes technology has revolutionized T1D management, disparities in technology access are evident among racial-ethnic minorities, patients with lower socioeconomic status and those with poorly controlled T1D (A1c\>8.5%). In order to examine whether diabetes technology can reduce diabetes care burdens and enhance outcomes among some of highest need patients, diabetes technology clinical trials must be expanded beyond the very select populations included in studies thus far (ie., mostly White, higher SES). Therefore, the investigators propose to perform a pilot RCT of hybrid closed-loop insulin pump therapy (HCL) in 40 diverse adult patients with poorly controlled T1D (HbA1c \>8.5%) from the largest academic and safety net health systems in the Los Angeles region to determine the feasibility of a RCT in this population and identify facilitators and barriers of effective use of closed loop insulin pump therapy in patients with poorly controlled T1D.

Conditions

• Diabetes Mellitus, Type 1

Interventions

Type	Name	Description
DEVICE	Hybrid Closed Loop Insulin Pump System	Patients will be started on an automated insulin delivery system.

Timeline

• Start date: 2024-09-05
• Primary completion: 2027-01-31
• Completion: 2027-06-01
• First posted: 2024-06-12
• Last updated: 2026-02-13

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated device study